Q-omics provides the consensus-scored GRIN2B profile across patient tissues and cancer cell-line models. GRIN2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GRIN2B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, GRIN2B RNA expression shows 12,504 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, COAD, and TGCT as cancer lineages where GRIN2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIN2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIN2B survival associations across molecular data types. GRIN2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIN2B RNA expression–survival associations across cancer types. High GRIN2B expression shows unfavorable associations in KICH, LUAD, UVM and UCEC, but favorable associations in UCS and SCLC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GRIN2B RNA expression.
This table summarizes GRIN2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIN2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIN2B shows lower tumor expression in LIHC, THCA and BRCA and higher tumor expression in COAD, STAD and READ. The COAD box plot shows higher GRIN2B RNA expression in tumor versus normal tissue (log2 FC = +0.590, t-test p < 0.001).
This table shows molecular features associated with GRIN2B in patient tissues and cancer cell lines. In patient samples, GRIN2B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIN2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
